What is the most commonly used class of antidepressants for treating depression in Parkinson’s disease patients?

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used class of antidepressants for treating depression in patients with Parkinson’s disease for several reasons.

Firstly, SSRIs are generally well-tolerated and have a favorable side effect profile compared to other antidepressant classes, making them easier to use in older patients who often have multiple comorbidities, as is common in those with Parkinson’s disease. Additionally, SSRIs are effective in addressing the specific symptoms of depression, which can significantly enhance the overall quality of life for these patients.

Secondly, SSRIs target serotonin pathways, which can be particularly relevant in Parkinson's disease, as patients often experience disruptions in mood and behavior due to the underlying neurodegenerative processes that affect neurotransmitter systems. The use of SSRIs can help mitigate these mood disturbances without exacerbating motor symptoms, which is a critical consideration in managing Parkinson's disease.

Other classes of antidepressants, such as tricyclic antidepressants, may have more side effects, including anticholinergic effects, that can worsen Parkinson’s symptoms. Non-selective MAO inhibitors have their own risks, such as potential dietary interactions and hypertensive crises. Serotonin and norepinephrine reuptake inhibitors can have effective